Ciproheptadin

Ciproheptadin
IUPACime
	4-(5H-dibenzo [a,d]ciklohepten-5-iliden)-1-metilpiperidin hidrohlorid
Klinički podaci
Prodajno ime	Periaktin
Drugs	Monografija
MedlinePlus	a682541
Kategorija trudnoće	US:B(Bez rizika u ispitivanjima na životinjama); ;
Način primene	Oralno
Pravni status
Pravni status	UK:Samo u apoteci;
Farmakokinetičkipodaci
Vezivanje proteina	96 do 99%
Metabolizam	Hepatičkiirenalno
Poluvreme eliminacije	8,6 sata
Izlučivanje	Fekalno i renalno
Identifikatori
CAS broj	129-03-3969-33-5 (hidrohlorid)
ATC kod	R06AX02(WHO)
PubChem	CID2913
IUPHAR/BPS	277
DrugBank	DB00434
ChemSpider	2810
UNII	2YHB6175DO
KEGG	D07765
ChEBI	CHEBI:4046
ChEMBL	CHEMBL516
Hemijski podaci
Formula	C21H21N
Molarna masa	287,398 g/mol
	SMILES c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4; ;
	InChI InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3; Key:JJCFRYNCJDLXIK-UHFFFAOYSA-N;

Ciproheptadin(Periaktin) jeprva generacija antihistaminasa dodatnimantiholinergičnim,antiserotinergičnim,ilokalno anestetičkimsvojstvima.^[2]^[3]

Farmakologija

Ciproheptadin deluje kaoantagonist(iliinverzni agonistu zavisnosti od aktivnog mesta) na sledećimreceptorima:

H₁(~0,05 nM)^[4]>5-HT_2A(~2 nM)^[5]≈5-HT_2B(~1,5 nM)^[6]≈5-HT_2C(~2 nM)^[6]>mACh(M₁-M₅;~7-12 nM)^[7]≈D₃(~8 nM)^[8]

On ima slab, i verovatno zanemarljiv,afinitetza sledeća mesta vezivanja (K_i):

5-HT_1A(~60-100 nM)^[5]^[8]≈α₁-adrenergički(?? nM)^[9]≈α₂-adrenergički(?? nM)^[9]>5-HT₆(~135-150 nM)^[10]^[11]≈5-HT₇(~125 nM)^[11]≈D₁(~115 nM)^[8]≈D₂(~115 nM)^[8]>5-HT_3</sub>(~250 nM)^[8]^[12]≈NET(~300 nM)^[13]

Pored toga, ciproheptadin poseduje osobineblokatora kalcijumskog kanala^[14]ilokalnog anestetika.^[15]

Reference

^Gunja N, Collins M, Graudins A (2004). „A comparison of the pharmacokinetics of oral and sublingual cyproheptadine”.Journal of Toxicology. Clinical Toxicology.42(1): 79—83.PMID 15083941.
^Hardman JG, Limbird LE, Gilman AG (2001).Goodman & Gilman's The Pharmacological Basis of Therapeutics(10. изд.). New York: McGraw-Hill.ISBN 0071354697.doi:10.1036/0071422803.
^Pdr Staff (2009).PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)).Rozelle, N.S.W: Thomson Reuters.ISBN 1-56363-748-0.
^Moguilevsky, N.; F, Varsalona; Noyer, M.; et al. (1994).„Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene”.European Journal of Biochemistry / FEBS.224(2): 489—95.PMID 7925364.doi:10.1111/j.1432-1033.1994.00489.x.
^^а ^бPeroutka, S. J. (1988).„Antimigraine drug interactions with serotonin receptor subtypes in human brain”.Annals of Neurology.23(5): 500—4.PMID 2898916.doi:10.1002/ana.410230512.
^^а ^бBonhaus, D. W.; Weinhardt, K. K.; Taylor, M.; et al. (1997). „RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist”.Neuropharmacology.36(4–5): 621—9.PMID 9225287.doi:10.1016/S0028-3908(97)00049-X.
^Stanton T, Bolden-Watson C, Cusack B, Richelson E (1993). „Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics”.Biochemical Pharmacology.45(11): 2352—4.PMID 8100134.doi:10.1016/0006-2952(93)90211-E.
^^а ^б ^в ^г ^дToll, L.; Berzetei-Gurske IP; Polgar, W. E.; et al. (1998). „Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications”.NIDA Research Monograph.178:440—66.PMID 9686407.
^^а ^бDukhovich, F. S. (15. 8. 2005).Pharmacological aspects of molecular recognition.Nova Publishers. стр. 117.ISBN 978-1-59454-676-1.Приступљено27. 11. 2011.
^Kohen, R.; Metcalf, M. A.; Khan, N.; et al. (1996).„Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor”.Journal of Neurochemistry.66(1): 47—56.PMID 8522988.doi:10.1046/j.1471-4159.1996.66010047.x.
^^а ^бBard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (1993). „Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase”.The Journal of Biological Chemistry.268(31): 23422—6.PMID 8226867.
^Hoyer D, Neijt HC (1988). „Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding”.Molecular Pharmacology.33(3): 303—9.PMID 3352595.
^Runyon SP, Savage JE, Taroua M, Roth BL, Glennon RA, Westkaemper RB (2001).„Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene”.Bioorganic & Medicinal Chemistry Letters.11(5): 655—8.PMID 11266163.doi:10.1016/S0960-894X(01)00023-3.
^Lowe DA, Matthews EK, Richardson BP (1981).„The calcium antagonistic effects of cyproheptadine on contraction, membrane electrical events and calcium influx in the guinea-pig taenia coli”.British Journal of Pharmacology.74(3): 651—63.PMC2071752 .PMID 6271323.
^F, Riccioppo Neto (1979). „The local anesthetic effect of cyproheptadine on mammalian nerve fibres”.European Journal of Pharmacology.54(3): 203—7.PMID 428422.doi:10.1016/0014-2999(79)90078-5.

Literatura

Dukhovich, F. S. (2005).Pharmacological aspects of molecular recognition.Nova Publishers. стр. 117.ISBN 978-1-59454-676-1.Приступљено27. 11. 2011.

Spoljašnje veze

Molimo Vas, obratite pažnju navažno upozorenje
u vezi sa temama izoblasti medicine (zdravlja).

[pmid15083941-1] Gunja N, Collins M, Graudins A (2004). „A comparison of the pharmacokinetics of oral and sublingual cyproheptadine”.Journal of Toxicology. Clinical Toxicology.42(1): 79—83.PMID 15083941.

[Goodman_Gilman-2] Hardman JG, Limbird LE, Gilman AG (2001).Goodman & Gilman's The Pharmacological Basis of Therapeutics(10. изд.). New York: McGraw-Hill.ISBN 0071354697.doi:10.1036/0071422803.

[PDR-3] Pdr Staff (2009).PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)).Rozelle, N.S.W: Thomson Reuters.ISBN 1-56363-748-0.

[pmid7925364-4] Moguilevsky, N.; F, Varsalona; Noyer, M.; et al. (1994).„Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene”.European Journal of Biochemistry / FEBS.224(2): 489—95.PMID 7925364.doi:10.1111/j.1432-1033.1994.00489.x.

[pmid2898916-5] а ^бPeroutka, S. J. (1988).„Antimigraine drug interactions with serotonin receptor subtypes in human brain”.Annals of Neurology.23(5): 500—4.PMID 2898916.doi:10.1002/ana.410230512.

[pmid9225287-6] а ^бBonhaus, D. W.; Weinhardt, K. K.; Taylor, M.; et al. (1997). „RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist”.Neuropharmacology.36(4–5): 621—9.PMID 9225287.doi:10.1016/S0028-3908(97)00049-X.

[pmid8100134-7] Stanton T, Bolden-Watson C, Cusack B, Richelson E (1993). „Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics”.Biochemical Pharmacology.45(11): 2352—4.PMID 8100134.doi:10.1016/0006-2952(93)90211-E.

[pmid9686407-8] а ^б ^в ^г ^дToll, L.; Berzetei-Gurske IP; Polgar, W. E.; et al. (1998). „Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications”.NIDA Research Monograph.178:440—66.PMID 9686407.

[Dukhovich2005-9] а ^бDukhovich, F. S. (15. 8. 2005).Pharmacological aspects of molecular recognition.Nova Publishers. стр. 117.ISBN 978-1-59454-676-1.Приступљено27. 11. 2011.

[pmid8522988-10] Kohen, R.; Metcalf, M. A.; Khan, N.; et al. (1996).„Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor”.Journal of Neurochemistry.66(1): 47—56.PMID 8522988.doi:10.1046/j.1471-4159.1996.66010047.x.

[pmid8226867-11] а ^бBard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (1993). „Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase”.The Journal of Biological Chemistry.268(31): 23422—6.PMID 8226867.

[pmid3352595-12] Hoyer D, Neijt HC (1988). „Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding”.Molecular Pharmacology.33(3): 303—9.PMID 3352595.

[pmid11266163-13] Runyon SP, Savage JE, Taroua M, Roth BL, Glennon RA, Westkaemper RB (2001).„Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene”.Bioorganic & Medicinal Chemistry Letters.11(5): 655—8.PMID 11266163.doi:10.1016/S0960-894X(01)00023-3.

[pmid6271323-14] Lowe DA, Matthews EK, Richardson BP (1981).„The calcium antagonistic effects of cyproheptadine on contraction, membrane electrical events and calcium influx in the guinea-pig taenia coli”.British Journal of Pharmacology.74(3): 651—63.PMC2071752 .PMID 6271323.

[pmid428422-15] F, Riccioppo Neto (1979). „The local anesthetic effect of cyproheptadine on mammalian nerve fibres”.European Journal of Pharmacology.54(3): 203—7.PMID 428422.doi:10.1016/0014-2999(79)90078-5.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]